Background: Low intensity transcranial focused ultrasound (tFUS) is a new method of noninvasive neuromodulation that uses acoustic energy to affect neuronal excitability. tFUS offers high spatial resolution and adjustable focal lengths for precise neuromodulation of discrete regions in the human brain. Before the full potential of low intensity ultrasound for research and clinical application can be investigated, data on the safety of this technique is indicated. Objective/Hypothesis: To provide an initial evaluation of the safety of tFUS for human neuromodulation through participant report and neurological assessment surrounding pilot investigation of tFUS for neuromodulation. Methods: Participants (N = 120) that were enrolled in one of seven human ultrasound neuromodulation studies at the University of Minnesota (2015 -2017) were queried to complete a follow-up Participant Report of Symptoms questionnaire assessing their self-reported experience and tolerance to participation in tFUS research and the perceived relation of symptoms to tFUS. Results: A total of 64/120 participant (53%) responded to follow-up requests to complete the Participant Report of Symptoms questionnaire. During the conduct of the seven studies in this report, none of the participants experienced serious adverse effects. From the post-hoc assessment of safety using the questionnaire, 7/64 reported mild to moderate symptoms, that were perceived as 'possibly' or 'probably' related to participation in tFUS experiments. These reports included neck pain, problems with attention, muscle twitches and anxiety. The most common unrelated symptoms included sleepiness and neck pain. There were initial transient reports of mild neck pain, scalp tingling and headache that were extinguished upon follow-up. No new symptoms were reported upon follow up out to 1 month.
Introduction
Transcranial focused ultrasound (tFUS) is a new and promising non-surgical low-energy technique that uses mechanical energy to modulate neuronal activity with high spatial resolution and adjustable depth of focus. tFUS has been used safely and effectively for cortical neuromodulation in mouse [1] [2] [3] [4] , rat [5, 6] , rabbit [7] , sheep [8] , pig [9] and monkey [10, 11] models, and has also been demonstrated to be an effective method of transient cortical and sub-cortical neuromodulation in humans [12, 13] . In humans, tFUS has been applied to the temporal cortex [14] , primary somatosensory cortex (S1) [12, 15] , secondary somatosensory cortex (S2) [16] , primary motor cortex [17, 18] , primary visual cortex [19] and thalamus [13, 20] . tFUS has been shown to affect the amplitude of evoked potentials [7, 12, 15] , the power, phase and frequency of the electroencephalogram (EEG) [12, 21] ; the blood oxygen level dependent (BOLD) magnetic resonance imaging signal [7, 17] , as well as tactile [12, 15] and reaction time [18] behaviour. In 2014, we found that tFUS targeted at the primary somatosensory cortex in healthy human subjects attenuated the somatosensory evoked potentials generated in the targeted region. These results were specific to the site of neuromodulation and also resulted in a behavioural advantage on somatosensory discrimination tasks [12] .
As currently employed, human neuromodulation with tFUS typically involves coupling a single (or multiple [16] ) focused single-elements usually in the ~ 250 to 600 kHz range (for efficient energy transfer through skull [22] ) to the scalp to target a desired brain region. Transducers for cortical targeting are generally small (~ 30 mm diameter with a ~ 30 mm focal length); produce a ~ 3-4 millimeter lateral and ~1 -2 centimeter axial resolution, and can be placed anywhere on the head similar to other current methods of non-invasive brain stimulation. Ultrasound is also capable of reaching brain targets deep to the cortical surface as the acoustic waves can be focused to any desired depth within certain limits. Transducers for deep brain modulation are typically larger ( ~ 70 mm diameter) [13, 20] to achieve this deeper focal length at reasonable axial resolutions [13] . In addition to adjusting focal lengths, there are a number of parameters that can manipulated when using ultrasound including the acoustic frequency, amplitude, duration, duty cycle, pulse repetition frequency etc. and the efficacy of some of these for successful neuromodulation has been addressed in small animal studies [1, 3] though the precise mechanism of acoustic energy for neuronal modulation is largely theoretical [23] [24] [25] and the impact of parameter space in humans is not yet well-described. The bioeffects of ultrasound for neuromodulation in humans as described here are likely largely mechanical as opposed to thermal as the parameters used are of low intensity and duration and do not generate sufficient temperatures for thermal modulation [26] . Ultrasound for transient neuromodulation is different from the use of ultrasound for surgery where very high intensities are used to thermally ablate tissues [27, 28] or for blood-brain barrier (BBB) opening where high intensities are also used in combination with contrast agents (microbubbles) to intentionally produce cavitation as a means of opening the BBB [29, 30] .
In its current state, ultrasound for neuromodulation generally follows the safety guidelines of the Food and Drug Administration (FDA) for obstetric diagnostic ultrasound and adult cephalic applications [31] . These include derated limits of spatial peak pulse average (I sppa ) of 190 W/cm 2 , a spatial peak temporal average of 720 mW/cm 2 (94 mW/cm 2 for adult cephalic) and a mechanical index (MI = peak negative pressure/√fc) of 1.9 (MI is an indication of the ability to produce cavitation related bio-effects and can be used as an indication for potential micromechanical damage). These levels of energy are generally respected in human ultrasonic neuromodulation studies even though there are no definitive guidelines for energy deposition into the human brain. There is a long history of ultrasound for diagnostic and therapeutic applications, but explicit expository and dosimetry are still largely lacking [32, 33] . There are several thorough reports examining the effect different intensities of ultrasound to affect tissue [34, 35] and efforts made to develop thresholds for potential hazards [36, 37] though these studies typically use continuous wave schemes and high intensities well beyond the levels used for transient neuromodulation and therefore are not wholly informative for low intensity applications. As such, it is important to assess the safety of ultrasound for human neuromodulation. It is the purpose of this paper to provide an initial assessment of the safety of single element focused ultrasound for human neuromodulation as there is yet any research on participant perceived tolerance and report of symptoms. Here, we report on the findings of a variant of the Participant Report of Symptoms questionnaire [38, 39] assessing participants' perceived tolerance to participation in tFUS and their perceived relation of any symptoms to the ultrasound intervention. Of a group of 120 queried, a total of (N = 64) consented to completing the questionnaire at various time points from immediately post-experiment out to 22 months.
Material and methods

Participants.
All experiments were conducted with the approval of the Institutional Review Board at the identified for transcranial magnetic stimulation [40] .
Experiments
The data for this study is a summary of 64 individual participants that participated in one of seven current or completed experiments conducted in our lab in the Department of Rehabilitation Medicine at the University of Minnesota. Details of the specific objectives or hypotheses of each study are not elaborated upon though details on the tFUS application including transducer specifics, target (cortical, sub-cortical) and parameters (amplitude, duration, etc.) are enumerated. For the purposes of this report, experiments will be referred to by number (1-7) based upon chronological date of commencement. All experiments were conducted in neurologically healthy volunteer participants to test the effect of tFUS on either cortical or sub-cortical [18] neuronal excitability and/or effect on specific behaviours. The environment of the experiments differed as one experiment (Experiment 4) [41] was conducted in a 7T MRI scanner at the Center for Magnetic Resonance Research at the University of Minnesota (https://www.cmrr.umn.edu) and experiment 6 and 7 also involved transcranial magnetic stimulation (TMS) either concurrent with tFUS [18] or as a pre/post measure of motor cortical excitability. For all experiments (except fMRI experiment), participants were seated in a dentist-type chair and asked to either perform a simple task or sit passively for the duration of the experimental protocol. Tasks included a sensory discrimination task [12] and simple stimulus response tasks on a computer. All experiments were repeated measures design with either one of or both an active or passive sham along with the tFUS condition. See Table 1 for experiment recruitment totals and participant demographics.
Questionnaire and follow-up
For all experiments, participants were retrospectively contacted via email at random time used the same transducer. See Figure 1 for the general ultrasound pulsing strategy and see Table 2 and Table 3 for transducer specifications and stimulation parameters for each study.
Results
Response rate
A total of 64/120 (53.3%) participants responded to the email regarding follow-up questionnaire.
The mean age of the participants was 22.96 ± 2.14 years (29 Male, 35 Female). See Table 1 for individual experiment demographics and response rates. The time of response post experimental participation ranged from 1 month to 22 months after participation for experiments 1-6 (see Figure 2A ). For experiment 7, 17 participants responded to the questionnaire immediately post experiment and then were contacted at a random time post experiment out to one month ( Figure 2B ).
Symptoms reported
Data from all seven experiments revealed 7/64 reported mild or moderate symptoms that they felt were 'possible' or 'probably' related to the ultrasound intervention. These included neck pain, difficulty paying attention, muscles twitches and anxiety. There were no reports of any severe or persistent symptoms. Of the other reported conditions, participants rated these as unrelated or unlikely related to the ultrasound intervention (see Figure 3 ). The most common reported symptom was sleepiness though this was rated as unrelated or unlikely for all instances. Other responses included headache (n = 4), itchiness (n = 5), tooth pain (n = 1) and forgetfulness (n = 4). No participant rated any reported symptom as definitely related to the ultrasound intervention (see Figure 3 ). There were no qualitative differences in the symptomology between experiments. See Figure 4 for a breakdown of symptoms by experiment for experiments 1-6.
Duration of symptoms
In a subset of participants (n = 17) for experiment 7 we collected response to the questionnaire at two time points: immediately following experimentation (~ 20 minutes) and then at a randomly assigned follow-up at 1 week, 2 weeks, 3 weeks or 1 month (see Figure 2B ). On day zero, there were three reports of neck pain, three reports of sleepiness, one report of scalp tingling, one report of tooth pain, one report of difficulty paying attention and one report of feeling anxious, worried or nervous and one 'other' report of mild back pain (see Figure 5 ). No participant reported more than one symptom at initial inquiry. Of these reports neck pain was perceived as unrelated in two instances and possible in one. Sleepiness was perceived as unrelated in two instances and unlikely in the other. Tingling of the scalp was perceived as possibly related to the intervention, difficulty paying attention was unlikely, tooth pain was unlikely and anxiousness was perceived as possibly related ( Figure 5 ). At follow-up (1 week to 1 month) these participants did not report any persisting or new effects ( Figure 5 ). Of the 7 participants who did not report any initial symptoms, none reported additional symptoms at follow-up ( Figure 5 ). Figure 6A ). The linear correlation of the response rate percentage and mechanical index (MI) was not significant (r = 0.633, p = 0.13) whereas intensity (I sppa ) was found to have a significant positive correlation with response rate; r = 0.797, p = 0.0319 ( Figure 6B ).
Correlation of symptom response to tFUS parameters
Discussion
In this report, we provide an initial safety analysis of single element tFUS for human neuromodulation. We collected retrospective data via a participant report of symptoms questionnaire administered over the telephone at varying time points post experiment that ranged from 0 months (day of experiment collected in person) to 22 months post experiment. 64/120 total participants responded to the questionnaire. Symptoms included headache, neck pain, itchiness, sleepiness, problems with attention, tooth pain, muscle twitches, anxiety and forgetfulness. None of these reports were rated as severe and none were reported as definitely related to the tFUS intervention. A subset of participants took the questionnaire immediately after experimentation. Immediate symptoms included mild headache, mild neck pain, and tingling in the scalp. None of these symptoms persisted and no new symptoms were reported upon follow-up out to 1 month. The intensity (I sppa ) of ultrasound ranged from 11.56 W/cm 2 to 17.12 W/cm 2 (in free water) for the experiments included in this study and we found a significant positive linear correlation of the symptom response rate and the ultrasound intensity (I sppa ). The intensity (I sppa ) used in these studies is considerably lower than FDA thresholds for ultrasound diagnostics. Despite a lack of definitive causation, and the finding that most of the reported symptoms were believed by the participants to be unrelated to the tFUS intervention, this finding nevertheless speaks to limiting the intensity used in future ultrasound experiments and determining as low as reasonably achievable levels for neuromodulation. Despite the I sppa level being below FDA thresholds, the I spta (spatial peak temporal average) in these studies was above FDA thresholds for diagnostics. I spta is simply the I sppa multiplied by the duty factor providing a metric of the average intensity over the duration of the pulse. One of the main concerns of determining safe intensity levels is estimating the intracranial pressure. The intensities presented here were taken from empirical recordings in free water and hence the derated intensities will be considerably lower. The skull is highly attenuative to ultrasound and the in situ derated pressures are not exactly known but can be estimated using either empirical pressure measurements using a hydrophone through skull fragments or through computer modelling that takes into consideration the acoustic properties of bone and tissue [12, 19, 42] .
For low intensity neuromodulation, in general, ultrasound intensity intracranially is estimated to be attenuated ~3 -4 fold from values measured in free water [12, 13, 19] and would thus produce I spta values under the FDA recommended limits for obstetric diagnostics (720 mW/cm 2 ) [31] .
The experiments documented here had a rather small range of I sppa though used considerably different number of stimulations and different inter-stimulus intervals that would contribute to overall exposure and may influence potential hazard. Indeed, found that a high number of total stimulations (600) with a low ISI (1 second) resulted in evidence of microhemmorage in sheep despite the intensity being rather low at 6.6 W/cm 2 [8] . It is currently unclear what constitutes a high number of stimulations or a low ISI though taking these experimental parameters into consideration in the planning of experimental design is prudent. Additional metrics like energy density (J/cm 2 ) as has been used in ultrasound sonoporation [43] and neuromodulation parameter [1] studies, as well as the total experimental energy density (J/cm 2 ) that takes into account intensity, duty cycle as well as total number of stimulations and the ISI would prove an additional valuable safety metric given the results of [8] though the relation of total experimental energy density to hazard is not well understood. Experiments examining these assertions are currently being conducted in our lab.
Despite the differences in total number of stimulations and ISI in the experiments reported here, there were no qualitative differences in response rate or in the type of report of symptoms between the seven experiments. The overall symptom response rate and type of symptoms is similar to other forms of non-invasive neuromodulation such as transcranial magnetic stimulation (TMS) and transcranial electric stimulation (TES) [44] [45] [46] [47] [48] . In addition to our group, Yoo's lab has performed human ultrasound neuromodulation studies and completed thorough safety analysis including similar telephone follow-up as well as neurological assessment pre and post experiment including anatomical MRI and reported zero events from their three studies [15, 16, 19] . In the published literature (N = 233) [12] [13] [14] [15] [16] [17] [18] [19] 41, 49] and including the experiments in this study, a total of 260 individuals have participated in human ultrasound neuromodulation experiments to date with no reported serious adverse events and the data from this report is the first to report on minor transient events associated with the tFUS intervention. Caution is always advised when imparting energy into the brain and further research is recommended examining the effect of total number of stimulations and the interstimulus interval and the potential interaction of these parameters with intensity and duty cycle.
Consideration of these parameters should be undertaken in experimental design to keep total experimental energy levels as low as reasonably achievable.
Conclusions
We provide an initial assessment of the safety of ultrasound for human neuromodulation as assessed by participant report of symptom questionnaire. Symptom rate and type are similar to other forms of human non-invasive neuromodulation like TMS and tDCS that have a long standing history of being safe forms of human neuromodulation. 
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